In the present study, we explored the molecular responses of FMS‐like tyrosine kinase 3/internal tandem duplication–mutated (FLT3/ITD+) AML cells to cytarabine and the highly selective FLT3 inhibitor quizartinib under O2‐controlled conditions in vitro. The gene discussed is FLT3; the disease is acute myeloid leukemia.